SciSparc Ltd

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2023

JV Targets Potential Drugs for Cancers and Infectious Diseases

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that the Company's board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value.

SciSparc's Board of Directors Provides Strategic Decision

NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).

TEL AVIV, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $10 million, before deducting fees to the placement agent and other expenses payable by the Company.

SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons ' Trap and Target TM technology

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems

TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market

Guardion Health Sciences Inc

The Very Good Food Co

Which penny stocks are you watching today? The post Best Penny Stocks to Watch as the Market Turns Bullish Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch as the Market Turns Bullish Today

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome

Didi Global

Geovax Labs

Are these penny stocks on your list right now? The post 3 Penny Stocks Worth Watching This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Worth Watching This Week

P re-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption

SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment

TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (the “SEC”).

SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update

Research to build on studies with support from global experts in the field of small molecule drugs and gene editing Research to build on studies with support from global experts in the field of small molecule drugs and gene editing

SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

Allego NV

Alpha Tau Medical

Forge Global Holdings Inc

Leafly Holdings

JX Luxventure Ltd

Miromatrix Medical Inc

NeuroSense Therapeutics Ltd

Kidpik Corp

Society Pass

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

12 Stocks Halted On A Circuit Breaker This Week

TEL AVIV, Israel, March 17, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced positive results from a pre-clinical trial as part of its ongoing collaboration agreement with Clearmind Medicine Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial

TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture ("JV") to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions.

SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

TEL AVIV, Israel, March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that it has entered into a collaboration agreement with Clearmind Medicine Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0) to explore the potential for the creation of innovative compounds in the psychedelic area.

SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals

TEL AVIV, Israel, Feb. 22, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that it will present a company overview at the Aegis Capital Corp. ("Aegis") Virtual Conference on February 24th at 8:30 a.m.

SciSparc to Present at Aegis Virtual Conference

TEL AVIV, Israel, Jan. 27, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), announced that its board of directors (the "Board") resolved to appoint Mr.

SciSparc Presents New Leadership Lineup

TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that it has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study for SCI-110, the Company's proprietary drug candidate, for patients suffering from Tourette syndrome (the "Study" or the "Trial").

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110

TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.

SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio

TEL AVIV, Israel, Jan. 6, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that The Israeli Medical Center for Alzheimer's has recruited the first patient to participate in the Company's Phase IIa clinical trial that will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation using the Company's proprietary cannabinoid-based technology.

SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease

TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), marks today one of the Company's most important milestones to date - the U.S. Patent and Trademark Office has granted it a new patent - U.S. Patent No.

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

TEL AVIV, Israel, Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today provides updates regarding its activities in 2021.

SciSparc Provides Updates Upon Conclusion of 2021

TEL AVIV, Israel, Dec. 22, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that its ordinary shares will start trading today on The Nasdaq Capital Market ("Nasdaq") under the symbol "SPRC.

News for SciSparc Ltd Stock (SPRC)